National Bard Ventralex Hernia Mesh Litigation Attorneys

The Bard Ventralex ST Hernia Mesh, composed of woven polypropylene mesh with a Seprafilm layer, has sparked legal action due to reported complications.

Bard’s Ventralex was initially approved by the FDA on July 16, 2002, through the 510(k) approval program. This program allowed Bard to skip pre-market clinical studies by claiming substantial similarity to its Kugel mesh.

In 2012, Bard issued a voluntary recall of Ventralex due to mislabeling. Some patches were packaged in cartons showing the wrong size. Bard advised customers to examine their inventory and quarantine affected products.

Litigation Update and Problems Associated with Bard’s Ventralex ST

Litigation with Hernia Mesh Synthetic hernia meshes, designed for permanent implantation, have raised concerns regarding mesh failure and associated complications. Trials are expected to examine Bard’s knowledge of the mesh’s ability to prevent adhesions, infections, and hernia recurrence.

Complications linked to hernia mesh include:

• Deep abdominal infections, especially if mesh erodes into the intestines
• Hernia recurrence due to mesh rejection, migration, or failure
• Inflammation and chronic pain
• Formation of internal scar tissue (adhesions) from foreign body reactions

Preserving Evidence

For potential litigations, preserving removed mesh is crucial, as it is patient property. Patients can request preservation or delivery of mesh to themselves or their legal representatives. Signing a medical release with a doctor may result in mesh return to the manufacturer without patient notification.

Contact Us for a Free Case Evaluation

If you or a loved one has suffered harm from Bard hernia mesh, Rheingold Giuffra Ruffo Plotkin & Hellman LLP can provide guidance and support. We lead hernia mesh litigations nationwide, offering compassionate advice and communication.